PRQR · ProQR Therapeutics N.V.
$1.70
+0.03 (+1.80%)
At close · Jul 17
Market Cap
$239.91M
Shares
141,121,476
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.70
Open$1.67
Day$1.62–1.76
52W$1.33–3.10
Avg vol 30d1.3M
Short int1.2M · 0.8% float · 1.0d
Short vol56%
DataJan 2020–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
+5%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
21%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
−3%
trailing
YTD return
−16%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
3 of 69 funds reported for Jun 30 · net -105.0K sh shares
Insider flow
Accumulating
Net +$730.5K over 90 days · 0% sells
Short interest
Rising
0.85% of float · ▲ +18.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
+5%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
3 of 69 funds reported for Jun 30 · net -105.0K sh shares
Insider flow
Accumulating
Net +$730.5K over 90 days · 0% sells
Short interest
Rising
0.85% of float · ▲ +18.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
69 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 21%
52-wk high $3
vs 200-day avg -9%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRQR
this stock
ProQR Therapeutics N.V.
|
$239.91M | -15.8% | — | — | 0.8% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRQR | -1.7% | +1.8% | -2.9% | -8.6% | -15.8% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -0.2% | +1.5% | -10.7% | -8.1% | -24.8% |